Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar;21(3):e202301389.
doi: 10.1002/cbdv.202301389. Epub 2024 Feb 23.

Pirfenidone: A Promising Drug in Ocular Therapeutics

Amol Chhatrapati Bisen  1   2 , Sristi Agrawal  1   2 , Ramakrishna Rayiti  1   2 , Sachin Nashik Sanap  1   2 , Arpon Biswas  1 , Anjali Mishra  1 , Neeraj Mohan Gupta  3 , Rabi Sankar Bhatta  1   2
Affiliations
Review

Pirfenidone: A Promising Drug in Ocular Therapeutics

Amol Chhatrapati Bisen et al. Chem Biodivers. 2024 Mar.

Abstract

Pirfenidone, initially indicated for lung fibrosis, has gone beyond its original purpose, and shown promise in eye care. This detailed review tracks its evolution from lung treatment to aiding eye healing as evidenced by published literature. Pirfenidone's multifaceted attributes extend to mitigating corneal fibrosis, inflammation, and trauma. Through rigorous investigations, its efficacy emerges in diabetic retinopathy, macular degeneration, and postoperative glaucoma interventions. As an unheralded protagonist, pirfenidone reshapes ocular care paradigms, inviting renewed research opportunities.

Keywords: Ophthalmology; corneal wound; keratitis; ocular fibrosis; patents; proliferative vitreoretinopathy.

PubMed Disclaimer

References

    1. E. S. Kim, G. M. Keating, Drugs 2015, 75, 219-230.
    1. T. M. Dempsey, S. Payne, L. Sangaralingham, X. Yao, N. D. Shah, A. H. Limper, Ann. Am. Thorac. Soc. 2021, 18, 1121-1128.
    1. USFDA, 2014, FDA Approved Drug Products: Esbriet (pirfenidone) for oral use, Available from: https://www.accessdata.fda.gov/drugsatfda docs/label/2019/022535s012,208780s002lbl.pdf.
    1. H. Zhong, G. Sun, X. Lin, K. Wu, M. Yu, Invest. Ophthalmol. Vis. Sci. 2011, 52, 3136-3142.
    1. C. S. Medeiros, G. K. Marino, M. R. Santhiago, S. E. Wilson, Invest. Ophthalmol. Vis. Sci. 2018, 59, 4044-4053.

LinkOut - more resources